{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gord-in-children/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"5a628000-fddd-591e-aa4a-f3a5d27a3b54","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 4faab9a4-d7ea-4460-89d8-9e188bc1caed --><h2>Changes</h2><!-- end field 4faab9a4-d7ea-4460-89d8-9e188bc1caed -->","summary":null,"htmlStringContent":"<!-- begin item 7fc4ea56-3637-4153-bea3-c5bce01e60cc --><!-- begin field ee93dcb8-3eb0-4442-90d7-86309f161b3e --><p><strong>September 2020</strong> — minor update. The wording in the managing suspected GORD section was clarified.</p><p><strong>February 2019</strong> — reviewed. A literature search was conducted in February 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to recommendations have been made.</p><!-- end field ee93dcb8-3eb0-4442-90d7-86309f161b3e --><!-- end item 7fc4ea56-3637-4153-bea3-c5bce01e60cc -->","topic":{"id":"3450f996-245b-5f1c-9e7b-4ac79aed190b","topicId":"82055e52-e2bf-4f1f-b8dd-b6cfff4b5cba","topicName":"GORD in children","slug":"gord-in-children","lastRevised":"Last revised in September 2020","chapters":[{"id":"6dd62a16-ccde-575f-9138-028d0f7249d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5c4344fa-cc04-5c8a-8525-0117f05a2a3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95a987c9-7f19-57c2-82eb-6673330f1a33","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5a628000-fddd-591e-aa4a-f3a5d27a3b54","slug":"changes","fullItemName":"Changes"},{"id":"76aa1188-2e33-55c6-ba4c-d13b6c09db53","slug":"update","fullItemName":"Update"}]},{"id":"939fae21-c502-5912-ad61-afb229a9fac5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"23c2943f-6ecf-5571-a559-9818348552ba","slug":"goals","fullItemName":"Goals"},{"id":"caee2b08-a4c2-5fa3-8d43-130a043b68d9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5fb28217-0443-5bfa-a971-4909a5a6c93b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"72771ba0-2707-5c43-b059-6d539cc568df","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"33debdff-0f33-531f-b7c3-a3123aa752ac","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b53e0cd-2b10-5e6f-99ad-e832ae9dde2e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0534b6c6-d8fb-5482-910c-3890eccd28a1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b0622c3b-0b7d-5e06-ac6e-b48f44307885","slug":"definition","fullItemName":"Definition"},{"id":"6dc898dd-dd38-5627-be60-ce0f218fcc6f","slug":"causes","fullItemName":"Causes"},{"id":"71b6272e-eb35-5e68-8449-c464d77d7563","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"844a2a73-bae8-5ae2-a218-4de702392498","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7924f80b-3369-54d7-a800-9a0bb22a0242","slug":"complications","fullItemName":"Complications"},{"id":"6ef64f28-7f65-5aaa-8e40-c5ed7f3ead77","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1bff5828-94a1-5984-8ed1-8cde69104288","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fd58f48a-9a7b-50dd-9c0e-d1c4826f6326","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"4ab712ac-c731-5386-8b93-5afa98f37717","slug":"assessment","fullItemName":"Assessment"},{"id":"5e9aff96-e1cf-58e7-9de4-ffdfa742df08","slug":"differential-diagnosis-red-flag-features","fullItemName":"Differential diagnosis/'red flag' features"}]},{"id":"9ac089f7-44bb-5da5-87a5-a065775dcea0","fullItemName":"Management","slug":"management","subChapters":[{"id":"cfa333ea-866c-555f-8a74-08b659ba92cb","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"775cc2f7-5cf2-5e72-9ffe-a06fbbe7bc17","slug":"gavisconr-infant","fullItemName":"Gaviscon® Infant"},{"id":"0f6b46fc-04ae-528e-8a4f-182488436dd7","slug":"ranitidine","fullItemName":"Ranitidine"},{"id":"81949c9c-d9f4-5246-ba10-93e03d3d5c2b","slug":"omeprazole","fullItemName":"Omeprazole"}]},{"id":"033a9c06-1742-5548-9885-53d54c7cc3b0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"558cd112-f11b-5b2e-a9a9-80f699b1dee5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9f5b615b-0570-5ba7-8d7a-d4cc5a4dd033","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"30b65237-637c-50a8-90fe-3c945c1a3ee1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45d4b60b-a070-544b-9f14-bee3b54e7f3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58c86f1d-bcc1-59b5-90c0-4a4c75374532","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0691004e-29d1-5b9f-b06e-90eeba4ce3f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7490205e-5357-534e-bf5f-2f2aad729683","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"95a987c9-7f19-57c2-82eb-6673330f1a33","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"eac4779d-d377-5322-a547-5723d4b9c1dd","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field b9e60c49-4231-4eca-a5ae-9a0c84c1bc7a --><h3>Previous changes</h3><!-- end field b9e60c49-4231-4eca-a5ae-9a0c84c1bc7a -->","summary":null,"htmlStringContent":"<!-- begin item b282672c-1cc5-45ea-9d69-a75210f6d34c --><!-- begin field 704b9d98-af4a-4035-b011-ce25bc9a231a --><p><strong>February to March 2015</strong> — reviewed and updated. A literature search was conducted in February 2015 to identify evidence-based guidelines, UK policy systematic reviews and key randomized controlled trials (RCTs) published since the last review of this topic. The topic has been updated to reflect guidance issued in the National Institute for Health and Care Excellence (NICE) 2015 guideline <em>Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people</em>. The following changes have been made to this topic:</p><ul><li>A section on 'red flag' symptoms has been added, which may suggest an alternative diagnosis. The recommendations on referral for admission or specialist assessment have been changed, to be in line with recommendations from NICE.</li><li>The recommendation to eliminate cows' milk protein from the diet as a treatment option has been removed.</li><li>A recommendation to consider a 4 week trial of omeprazole or ranitidine has been inserted.</li><li>A prescribing information section has been added.</li></ul><p><strong>May 2014</strong> — minor update. Changes to the text to reflect advice from the European Medicines Agency (EMA) regarding metoclopramide and domperidone. Both are no longer recommended to treat dyspepsia or gastro-oesophageal reflux disease.</p><p><strong>January 2013</strong> — minor update. Change to the text to reflect advice from the Department of Health regarding reconstitution of infant formula.</p><p><strong>August to December 2009</strong> — this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 704b9d98-af4a-4035-b011-ce25bc9a231a --><!-- end item b282672c-1cc5-45ea-9d69-a75210f6d34c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}